{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T09:59:28Z","timestamp":1785059968948,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803070"],"award-info":[{"award-number":["81803070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12029-024-01095-7","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:19:04Z","timestamp":1722363544000},"page":"1388-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents"],"prefix":"10.1007","volume":"55","author":[{"given":"Yiran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"A-L Cheng","year":"2020","unstructured":"Cheng A-L, Hsu C, Chan SL, Choo S-P, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307\u201319.","journal-title":"J Hepatol"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz H-J, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","volume":"32","author":"EC Smyth","year":"2021","unstructured":"Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32:590\u20139.","journal-title":"Ann Oncol"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1095_CR6","first-page":"2946","volume":"10","author":"C Ren","year":"2020","unstructured":"Ren C, Mai Z-J, Jin Y, He M-M, Wang Z-Q, Luo H-Y, et al. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. Am J Cancer Res. 2020;10:2946\u201354.","journal-title":"Am J Cancer Res"},{"key":"1095_CR7","doi-asserted-by":"publisher","first-page":"952494","DOI":"10.3389\/fonc.2022.952494","volume":"12","author":"Q Cui","year":"2022","unstructured":"Cui Q, Mao Y, Wu D, Hu Y, Ma D, Zhang L, et al. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer. Front Oncol. 2022;12:952494.","journal-title":"Front Oncol"},{"key":"1095_CR8","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","volume":"15","author":"RWF van Leeuwen","year":"2014","unstructured":"van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315\u201326.","journal-title":"Lancet Oncol"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","volume":"51","author":"H Zhou","year":"2011","unstructured":"Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359\u201372.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1095_CR10","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer [Internet]. 2020\u00a0[cited 2022 Jan 14];8:e001361. https:\/\/doi.org\/10.1136\/jitc-2020-001361.","journal-title":"J Immunother Cancer [Internet]."},{"key":"1095_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/1759-7714.13470","volume":"11","author":"X Diao","year":"2020","unstructured":"Diao X. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer. Thorac Cancer [Internet]. 2020\u00a0[cited 2022 Jan 14];11:1763\u20134. https:\/\/doi.org\/10.1111\/1759-7714.13470.","journal-title":"Thorac Cancer [Internet]."},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1095_CR13","doi-asserted-by":"crossref","unstructured":"Nguyen QP, Nomura M, Matsumoto S, Muto M. The effect of proton pump inhibitors on the efficacy of nivolumab monotherapy in different types of cancer. Ann Oncol [Internet]. 2019 [cited 2022 Jan 14];30:vi115.\u00a0https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419622027.","DOI":"10.1093\/annonc\/mdz338.107"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1158\/1078-0432.CCR-04-1065","volume":"10","author":"M Yeo","year":"2004","unstructured":"Yeo M, Kim D-K, Kim Y-B, Oh TY, Lee J-E, Cho SW, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004;10:8687\u201396.","journal-title":"Clin Cancer Res"},{"key":"1095_CR15","doi-asserted-by":"crossref","unstructured":"Li Y, Ren B-X, Li H-M, Lu T, Fu R, Wu Z-Q. Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation. Acta Pharmacol Sin. 2022;43:1816\u201328.","DOI":"10.1038\/s41401-021-00787-1"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u201356.","journal-title":"Gut"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27\u201337.","journal-title":"Gut Liver"},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","volume":"27","author":"NM Kuderer","year":"2009","unstructured":"Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27:4902\u201311.","journal-title":"J Clin Oncol"},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-021-02712-w","volume":"19","author":"P Johannet","year":"2021","unstructured":"Johannet P, Sawyers A, Gulati N, Donnelly D, Kozloff S, Qian Y, et al. Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. J Transl Med. 2021;19:47.","journal-title":"J Transl Med"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"eaaw8405","DOI":"10.1126\/sciimmunol.aaw8405","volume":"4","author":"C Graf","year":"2019","unstructured":"Graf C, Wilgenbus P, Pagel S, Pott J, Marini F, Reyda S, et al. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. 2019;4:eaaw8405.","journal-title":"Sci Immunol."},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph10040078","volume":"10","author":"S Mohamed","year":"2017","unstructured":"Mohamed S, Coombe DR. Heparin mimetics: their therapeutic potential. Pharmaceuticals (Basel). 2017;10:78.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1095_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","volume":"33","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33:570\u201380.","journal-title":"Cancer Cell"},{"key":"1095_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ijc.33557","volume":"149","author":"K Takada","year":"2021","unstructured":"Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, et al. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: a multicenter retrospective survival analysis study with inverse probability of treatment weighting. Int J Cancer. 2021;149:473\u201382.","journal-title":"Int J Cancer"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol Res. 2020;8:1236\u201342.","journal-title":"Cancer Immunol Res"},{"key":"1095_CR25","doi-asserted-by":"crossref","unstructured":"Taniguchi Y, Tamiya A, Matsuda Y, Adachi Y, Enomoto T, Azuma K, Kouno S, Tokoro A, Atagi S. Opioids impair Nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. BMJ Support Palliat Care. 2023;13(e1):e185\u20139.","DOI":"10.1136\/bmjspcare-2020-002480"},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/mi.2016.9","volume":"9","author":"S Banerjee","year":"2016","unstructured":"Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol. 2016;9:1418\u201328.","journal-title":"Mucosal Immunol"},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36:2872\u20138.","journal-title":"J Clin Oncol"},{"key":"1095_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00280-019-03993-1","volume":"85","author":"A Schett","year":"2020","unstructured":"Schett A, Rothschild SI, Curioni-Fontecedro A, Kr\u00e4henb\u00fchl S, Fr\u00fch M, Schmid S, et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020;85:121\u201331.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01095-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:16:49Z","timestamp":1724671009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01095-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01095-7","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"20 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Sir Run Run Shaw Hospital of Zhejiang University (No. 20210405-36), The First Affiliated Hospital of Zhejiang University (No. IIT20230496A), and The Second Affiliated Hospital of Zhejiang University (No. 2023-0450). The Written informed consent was obtained from participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}